Home
Ruishikang
About Ruishikang
Company Profile
Jointly Creating a Healthy China
Corporate Culture
Listen to the voice of the CEO
Development History
Honor and Qualification
Sustainable Development
Memorabilia
Excellent Corporate Citizen
Ruishikang Global
Expert Advisor
Leadership in China Business
Core Team
The top leadership of the company
Product
Cosmetics
Culture Medium
Cell Line
Technical Service
Consulting Service
R&D
Research and Development Platform
R&D Pipeline
News
Industry News
Ruishikang News
Contact Us
中文
EN
Ruiyi Enterprising
Focus Areas
Tumor
Ruiyi Enterprising Together to Cure Cancer
Vaccinum
Vaccines make health within reach
Anti-Infection
Strive for AI comprehensively
Inflammation and immunity
Ruiyi Enterprising and Revitalizing
Rare Disease
Rui Yi Enterprising for Love and Care
Ruishikang China R&D Center
研发中心 |上海
研发中心 |武汉
Product pipeline
Innovative Product
Product List
Medical Information
News Center
Company News
Ruishikang Annual Report
About Ruishikang
Ruishikang Global
Global Overview
Ruiyi Enterprising
Management team
The highest leadership of the company
Ruishikang China
Overview of Ruishikang
Jointly Creating a Healthy China
Message from the President
Listen to the voice of the CEO
责任
Corporate Governance
Sustainable Development
Corporate Responsibility
Excellent Corporate Citizen
Career Development
Talent recruitment
中文 /
EN
成为中国首屈一指的
生物医药公司
Read More
Company News
2024-01-31
Ruishikang's research and development of new stem cell drugs for rheumatoid arthritis has entered th
More News
Science
肿瘤
疫苗
抗感染
炎症与免疫
罕见病
Innovative Product
Search for all products
Ruishikang Annual Report
In 2022, Ruishikang will once again bring positive changes to the world, benefiting countless patients, while also presenting a brilliant report card to employees, shareholders, and the whole society through numbers.
Ruishikang Annual Report